AlphAIAlphAI — Financial news for AI agents
rttnews.comOCT 271 min read$VNDA

Vanda Pharmaceuticals Announces Encouraging Data From NEREUS Phase 3 Study

Vanda Pharmaceuticals (VNDA) reported positive Phase 3 study results for NEREUS, showing a 27% reduction in vomiting episodes compared to placebo. The drug also met key secondary endpoints. Vanda plans to discuss results with the FDA and file a supplemental New Drug Application. VNDA stock was up 1.52% in pre-market trading.

Original reporting
rttnews.com
Published Oct 27, 2026, 11:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$VNDA
Bullish
high confidence
Mentioned
$VNDA
Relevance
9/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$VNDABullishMed
01

Why it matters

The Phase 3 data provide a strong efficacy signal, likely prompting a supplemental NDA and could materially affect the company's valuation.

02

Market read

Positive trial results are a catalyst for biotech stocks, especially those targeting GLP-1 side effects.

03

What to watch

Potential competition from other anti-nausea agents in GLP-1 space.

Relevance 9/10Novelty 9/10Timing: pre-market today

Background

Vanda Pharmaceuticals (NASDAQ: VNDA) is developing NEREUS to mitigate vomiting associated with GLP-1 receptor agonist therapies.

Company-level read

Ticker impact

$VNDABullishHigh confidence
Context

Vanda Pharmaceuticals reported positive Phase 3 data for NEREUS, showing a 27% reduction in vomiting episodes versus placebo.

Expected impact

upside pressure as investors price in possible approval and upcoming NDA filing

Evidence & confidence

Phase 3 success is material for a biotech and typically triggers a rally ahead of regulatory filing.

Market effects

Sector

May boost sentiment for anti-emetic and GLP-1 adjunct therapies across biotech sector.

Regional

US biotech stocks could see modest gains.

Global

Limited to investors tracking FDA pipeline developments.

Counterpoint

What could challenge this read

If regulatory hurdles arise, the rally could be short-lived.

Key entities

  • Company
    Vanda Pharmaceuticals Inc.

    Developer of NEREUS, a GLP-1 anti-emetic therapy.

Read at source← All news

StoryVanda reports Phase III trial shows NEREUS cuts GLP‑1‑induced vomiting

Also covered by

1 outlet

Related articles

OCT 27
$VNDAHighAI 8/10

Vanda reports positive trial results for GLP-1 vomiting drug

Vanda Pharmaceuticals (VNDA) reported positive Phase III trial results for NEREUS (tradipitant) in preventing vomiting in GLP-1 therapy patients. The study met primary and secondary endpoints, showing significant reductions in vomiting rates compared to placebo. VNDA plans to discuss results with the FDA and seeks approval for this new indication. The drug was well-tolerated with no new safety concerns.

investing.com2 min
OCT 27
$VNDAMedAI 8/10

Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting

Vanda Pharmaceuticals (VNDA) reported positive Phase III results for NEREUS™ (tradipitant) in preventing vomiting linked to GLP-1 therapies. The study showed significant reductions in vomiting (27% p=0.006), severe nausea (35% p=0.002), and extreme vomiting (81% p=0.0003). Vanda plans to discuss results with the FDA and submit an sNDA for this indication.

prnewswire.com3 min
OCT 16
$VNDAHighAI 8/10

Vanda Pharmaceuticals’ VQW-765 misses primary endpoint

Vanda Pharmaceuticals (VNDA) shares dropped 6.2% after hours as its Phase III trial for VQW-765 failed to meet the primary endpoint in treating acute anxiety in adults with social anxiety disorder. The study was a multicenter, randomized, double-blind, placebo-controlled trial conducted at 30 U.S. sites.

thepharmaletter.com1 min
OCT 15
$VNDAMedAI 8/10

Phase 3 Trial of VQW-765 for Social Anxiety Disorder Misses Endpoint

Vanda Pharmaceuticals' phase 3 trial for VQW-765, an investigational treatment for social anxiety disorder, missed its primary endpoint. The study showed no significant difference in distress levels between participants receiving VQW-765 and those receiving a placebo. The company is evaluating the data, and the clinical program is currently on hold.

empr.com4 min
OCT 15
$VNDAMed

Vanda freezes Novartis-originated social anxiety program after late-stage disappointment

Vanda Pharmaceuticals halted development of VQW-765, a social anxiety drug licensed from Novartis, after it failed to show significant benefit in a late-stage study. The Phase 3 trial, focused on female participants, showed no distress reduction versus placebo. Vanda will analyze the full dataset before deciding next steps. Oppenheimer analysts noted this was a clean miss but do not expect it to significantly impact their estimates for Vanda.

biospace.com5 min
OCT 15
$VNDAHighAI 8/10

Vanda Pharmaceuticals (VNDA) Shares Fall 2% Premarket After Phas

Vanda Pharmaceuticals (VNDA) shares fell 2% premarket after its Phase III trial for anxiety drug VQW-765 failed to meet primary and key secondary endpoints. The company paused the program for further analysis, confirming the drug's safety. VNDA's P/S ratio is 1.16, below historical and industry medians, reflecting market skepticism. Insider selling totaled $2.8M, with mixed institutional sentiment.

gurufocus.com2 min